Intestine-Specific, Oral Delivery of Captopril/Montmorillonite: Formulation and Release Kinetics
© Madurai et al. 2010
Received: 3 July 2010
Accepted: 5 August 2010
Published: 27 August 2010
The intercalation of captopril (CP) into the interlayers of montmorillonite (MMT) affords an intestine-selective drug delivery system that has a captopril-loading capacity of up to ca. 14 %w/w and which exhibits near-zero-order release kinetics.
KeywordsCaptopril montmorillonite Intercalation Intestine-specific controlled release Release kinetics
Captopril (CP; 1-[(2s)-3-mercapto-2-methyl propionyl]-L- proline), an orally active inhibitor of angiotensin-converting enzyme (ACE) [1, 2], is in many countries the medication of choice for the management of hypertension and is often used to treat some types of congestive heart failure [3–6]. CP contains a reactive thiol group, which is postulated to bind to the Zn2+ of the angiotensin-converting enzyme  and which forms the disulfide linkages with thiol-containing residues of plasma proteins that are responsible for the extensive tissue binding of the drug . Owing to its pKa (3.7 at 25°C), CP is highly soluble in water at acidic pH (125–160 mg/ml at pH 1.9). At pH > pKa, the amidic linkage of the molecule becomes increasingly susceptible to hydrolysis; under basic conditions, the drug exhibits a pseudo-first-order degradation reaction [9, 10].
In man, CP reduces plasma angiotensin II and aldosterone levels, increases plasma renin activity and produces a significant decrease in blood pressure in hypertensive patients . It blocks the enzyme system that causes the relaxation of artery walls, reducing blood pressure, decreasing symptoms of cystinuria and reducing rheumatoid arthritis symptoms. The duration of the antihypertensive action of a single oral dosing of CP is 6–8 h, with the implication that clinical administration requires the daily dose of 37.5–75.0 mg to be taken at 8-h intervals . The metabolic products of CP include a disulfide dimer of CP, a CP-cysteine disulfide and mixed disulfides with endogenous thio compounds . In efforts to reduce the frequency of administration, several attempts have been made to design sustained release formulations. These have included coated tablets [14–16], beadlets , hydrophobic tablets , pulsatile delivery systems , microcapsules , semisolid matrix systems , floating tablets and capsules , and bioadhesive polymers .
An evolving approach to controlled drug delivery involves the use of nanoclays with well-defined morphologies. Montmorillonite (MMT), a swelling clay mineral, is one such material that has shown considerable promise as a carrier in controlled drug delivery. Since the mineral is comprised of alternating negatively charged alumino-silicate layers with exchangeable counter ions positioned between each layer , the capability of the material to act as a controlled delivery vehicle is rationalized in terms of the potential for drug molecules to become adsorbed onto the hydrated alumino-silicate layers, which in aqueous media exist as dispersions of individual platelet. This paper describes an attempt to assess the suitability of MMT to act as a matrix for the controlled release of CP by evaluating intercalation data from three methods (solution, melt and grinding) and by considering the characteristics of CP release.
Materials and Methods
Preparation of CP-MMT Systems
Optimization of Clay Colloidal Dispersion
Solution Intercalation Method
To improve the cation exchange capacity (CEC) of the clay, MMT-K10 was treated with sodium chloride and the resultant Na-MMT dispersions were washed with deionised water (centrifugation) until a AgNO3 test confirmed that all chloride had been removed . CP (1.382, 2.765, 3.456 and 4.417 mM) was added to separate vessels containing the 5 %w/w Na-MMT aqueous dispersion (100 cm3) and maintained (stirring) at 50°C for 4 h. To remove any free drug, the intercalated particles were collected following repeated (4×; replacing the deionized water after each cycle) centrifugation (4,000 rpm, 20 min) of the dispersion. The isolated CP-MMT powder was dried in a vacuum oven, ground and stored in a desiccator. To assess the improvement in cation exchange capacity following treatment with sodium, samples of MMT were subjected to an identical procedure and used as controls.
Melt Intercalation Method
A mixture of MMT and CP (10:9 w/w) was heated (2°C/min) to the melting point of CP and maintained at that temperature for 6 h. The cooled (room temperature) residue was washed (3×) with deionised water and dried (room temperature) before use.
Grinding Intercalation Method
A mixture of MMT and CP (10:9 w/w) was ground finely (ca. 30 min) using a pestle and mortar, washed (deionised water, 3×) and dried (desiccator) before use.
In Vitro Drug Release
The simulated gastric fluid was a buffer solution (pH 1.2) that had been prepared by mixing 250 ml of aqueous HCl (0.2 M) with 147 ml of aqueous KCl (0.2 M). The simulated intestinal fluid was a buffer solution (pH 7.4) that had been prepared by mixing 250 ml of aqueous KH2PO4 (0.1 M) and 195.5 ml of aqueous NaOH (0.1 M) .
The drug release study was performed in a constant temperature bath (37°C) fitted with a rotating round-bottomed flask (100 rpm) by suspending a dialysis membrane bag containing 20 ml of CP-MMT dispersion in 900 ml of dissolution media. At specified time intervals, an aliquot (5 ml) of the dissolution medium was removed and the concentration of CP was determined by UV absorption measurements, respectively, at 205 and 217 nm for the acidic and basic buffers.
Drug Release Kinetics
To assess the kinetics of CP release, in vitro drug release data were fitted into established mathematical models.
where, Q o = initial amount of drug, Q t = cumulative amount of drug release at time t, K o = zero-order rate constant and t = time in h.
where, K1 = first-order rate constant.
where, Q = cumulative drug release at time t and K H = constant reflective of the design variables of the system.
Where, Mt/M∞ = fraction of drug released at time t, K = rate constant and n = release exponent.
Values of n between 0.5 and 1.0 are indicative of anomalous, non-Fickian, kinetics .
The concentration of CP was determined from calibration plots of absorbance (SHIMADZU UV 240 Spectrophotometer; quartz cell path length = 1 cm) at 205 nm or at 217 nm for the molecule in acidic or alkaline buffer, respectively. Infrared spectra (KBr disks) were recorded using a PERKIN-ELMER Spectrum RX1, FTIR V.2.00 spectrophotometer. X-ray diffraction (XRD) patterns were recorded using a SIEMENS D-500 variable angle diffractometer (CuKα source, λ = 1.5405 A°; 1–60°). Thermogravimetric determinations (37–800°C, 10°C/min; TA instruments TGA Q50) were carried out under nitrogen.
Results and Discussion
Basal spacings of CP-MMT systems, as determined by XRD
Drug loaded amount (mmol/g)
Interlayer distance (nm)
CP-MMT by solution
CP Release Profiles
Drug release profiles of CP-MMT systems
Drugloaded amount (mmol/g of clay)
Drug release rate (%) at
Drug Release Kinetics
Parameters for CP release at pH 1.2
Parameters for CP release at pH 7.4
CP has been confirmed to successfully intercalate into the interlayers of MMT. The maximum percentage of intercalated CP was determined as ca. 14 %w/w. In vitro release experiments have shown that the release of CP from the MMT matrix is sensitive to the pH of the dissolution media. The CP release rate in simulated intestinal fluid (pH 7.4) is significantly higher than that in simulated gastric fluid (pH 1.2) and exhibits near-zero-order release kinetics.
One of the authors (JWS) is grateful to CSIR for funding as a Project Assistant in the NWP-035 project.
- Ferguson RK, Brunner HR, Turini GA, Gavras H, McKinstry DN: Lancet. 1977, 1: 775. 10.1016/S0140-6736(77)92958-0View ArticleGoogle Scholar
- Ondetti MA, Rubin B, Cushman DW: Science. 1977, 196: 441. 10.1126/science.191908View ArticleGoogle Scholar
- Gavras H, Brunner HR, Turini GA, Kershaw GR, Tifft CP, Guttelod S, Gavras I, Ukovish RA, McKinstry DN: New Engl J Med. 1978, 298: 991. 10.1056/NEJM197805042981803View ArticleGoogle Scholar
- Bravo EL, Tarazi RC: Hypertension. 1979, 1: 39.View ArticleGoogle Scholar
- Brunner HR, Gavras H, Waebar B, Kershaw GR, Turini GA, Vukovish RA, McKinstry DN: Ann Intern Med. 1979, 90: 19.View ArticleGoogle Scholar
- Testa MA, Anderson RB, Nackley JF, Hollenberg NK: New Engl J Med. 1993, 328: 907. 10.1056/NEJM199304013281302View ArticleGoogle Scholar
- Antonaccio MJ: Ann Rev Pharmacol Toxicol. 1982, 22: 57. 10.1146/annurev.pa.22.040182.000421View ArticleGoogle Scholar
- Komai T, Ikeda T, Kawai K, Kameyama E, Shendo H: J Pharmacobio-Dynam. 1981, 4: 677.View ArticleGoogle Scholar
- Seta Y, Higuchi F, Kawahara Y, Nishimura K, Okada R: Int J Pharm. 1988, 41: 245. 10.1016/0378-5173(88)90201-3View ArticleGoogle Scholar
- Anaizi NH, Swenson C: Am J Hosp Pharm. 1993, 50: 486.Google Scholar
- Horovitz SP: Angiotensin Converting Enzyme Inhibitors, Mechanisms of Action and Clinical Implications: Procceedings of the A. N. Richards Symposium Sponsored by the Physiological Society of Philadelphia. Urban & Schwarzenberg, Baltimore-Munich; 1981.Google Scholar
- Miazaki N, Shionoiri H, Uneda S, Uneda G, Yasuda G, Gotoh E, Fujishima S, Kaneko Y, Kawahara Y, Yamazaki Y: Nippon Jinzo Gakkai Shi. 1982, 24: 421.View ArticleGoogle Scholar
- Migdalof BH, Wong KK, Lan SJ, Kripalani KJ, Singhvi SM: Fed Proc. 1980, 39: 757.Google Scholar
- Drost JD, Reier GE, Jain NB: U.S. Patent 4756911. 1988.Google Scholar
- Guittard GV, Carpenter HA, Quan ES, Wong PS, Hamel LG: US patent 5178867. 1993.Google Scholar
- Nahata MC, Morosco RS, Hipple TF: Am J Hosp Pharm. 1994, 51: 95.Google Scholar
- Joshi YM, Bachman WR, Jain NB: European Patent EP 288732 A2. 1988.Google Scholar
- Thakur AB, Jain NB: U.S. Patent 4738850. 1988.Google Scholar
- AprRashid A: British Patent Application 2230441A. 1990.Google Scholar
- Singh J, Robinson DH: Drug Dev Ind Pharm. 1988, 14: 545. 10.3109/03639048809151883View ArticleGoogle Scholar
- Matharu RS, Singhavi NM: Drug Dev Ind Pharm. 1992, 18: 1567. 10.3109/03639049209040859View ArticleGoogle Scholar
- DeCrosta MT, Jain NB, Rudnic EM: U.S. Patent 4666705. 1987.Google Scholar
- Sposito G, Skipper NT, Sutton R, Park SH, Soper AK, Greathouse JA: Proc Natl Acad Sci. 1999, 96: 3358. 10.1073/pnas.96.7.3358View ArticleGoogle Scholar
- Bergaya F, Theng BKG, Lagaly G: Handbook of clay science. Elsevier publication, Amsterdam; 2006.Google Scholar
- Ghanshyam VJ, Hasmukh AP, Bhavesh DK, Hari CB: Appl Clay Sci. 2009, 45: 248. 10.1016/j.clay.2009.06.001View ArticleGoogle Scholar
- Peppas NA, Sahlin JJ: Int J Pharm. 1989, 57: 169. 10.1016/0378-5173(89)90306-2View ArticleGoogle Scholar
- Reed-Hill RE, Abbaschain R: Physical metallurgy principles. 3rd edition. PWS publishing Company, Boston; 1994.Google Scholar
- Suguna Lakshmi M, Sriranjani M, Bava Bakrudeen H, Suresh Kannan A, Mandal AB, Reddy Boreddy SR: Appl Clay Sci. 2010, 48: 589. 10.1016/j.clay.2010.03.008View ArticleGoogle Scholar
- Pradhan R, Budhathoki U, Thapa P: J Sci Eng Technol. 2008, 1: 55.Google Scholar
- Korsmeyer RW, Gurny R, Doelker E, Buri P, Peppas NA: Int J Pharm. 1983, 15: 25. 10.1016/0378-5173(83)90064-9View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.